AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2557307
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily fractions to the liver (3.0 Gy external beam radiation, total dose 21.0 Gy) with chemotherapy (Adriamycin 15 mg IV and 5-FU 500 mg IV, 2 hr before treatment on days 1, 3, 5, and 7)
Trial: 2557307
Drug: Hyperfractionated whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated whole liver external beam irradiation (1.2 Gy twice daily, 4 hr between treatments, 5 days per week to 24.0 Gy, 10 MV photons) with the same chemotherapy regimen
Trial: 1149303
Drug: Apomorphine hydrochloride
RxNorm normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine hydrochloride (0.75 mg s.c.)
Trial: 1149303
Drug: L-DOPA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (500 mg p.o.)
Trial: 1149303
Drug: Benztropine mesylate
RxNorm normalized name: Benztropine Mesylate
DrugBank: Benzatropine (DB00245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benztropine mesylate (1 mg i.m.)
Trial: 28618299
Drug: Internet guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet guided self‐help cognitive‐behavioural treatment (ICBT)
Trial: 26441220
Drug: Continuous micropump
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous micropump infusion of atropine and pralidoxime chloride
Trial: 26441220
Drug: Repeated-bolus doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-bolus doses of atropine and pralidoxime chloride
Trial: 20209468
Drug: Pyruvate supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyruvate supplementation (2 g per day for 4 weeks)
Trial: 3934915
Drug: s.c. salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. salbutamol 0.5 mg
Trial: 3934915
Drug: Placebo 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 mg
Trial: 27724833
Drug: Psychotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy for TTM (details on dosage and duration not available)
Trial: 21535346
Drug: Sitagliptin/Metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/Metformin FDC
Trial: 21535346
Drug: Metformin Monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin Monotherapy
Trial: 11786454
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed (Group B)
Trial: 11786454
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics prescribed (Group A)
Trial: 8597968
Drug: Ilioinguinal-iliohypogastric nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal-iliohypogastric nerve block performed by anaesthetist using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Trial: 8597968
Drug: Ilioinguinal-iliohypogastric nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal-iliohypogastric nerve block performed by surgeon using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Trial: 2527678
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) plus once daily extended‐acting insulin)
Trial: 2527678
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily injections of short‐ and intermediate‐acting insulin
Trial: 7286051
Drug: Chlorthalidone 100
RxNorm normalized name: chlorthalidone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 100 mg
Trial: 334436
Drug: Chlorthalidone 200
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 200 mg
Trial: 334436
Drug: Chlorthalidone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (various doses)
Trial: 334436
Drug: Chlorthalidone (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (higher doses)
Trial: 27814327
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of absolute alcohol (ethanol)
Trial: 27814327
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of chlorpromazine (25 mg/mL)
Trial: 16880018
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire on hair removal practices and psychological impact
Trial: 1510408
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg, orally twice daily for 7 days)
Trial: 1510408
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg, orally twice daily for 7 days)
Trial: 6392936
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nadolol
Trial: 6392936
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nadolol and 5 mg bendroflumethiazide
Trial: 31655942
Drug: Traditional Lp(a)-lowering
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Lp(a)-lowering approaches (niacin, PCSK9 inhibitors, mipomersen, lomitapide, lipoprotein apheresis)
Trial: 27175476
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PGJ) (250 g)
Trial: 27175476
Drug: Fermented sour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented sour sobya (FS) (170 g)
Trial: 27175476
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of PGJ (150 g) and FS (140 g)
Trial: 27175476
Drug: Fresh apricot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh apricot fruits (200 g)
Trial: 22685234
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg/d; n = 25)
Trial: 17850670
Drug: Tablet PC-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PC-based video (Trial Two)
Trial: 10428345
Drug: 50-g glucose
RxNorm normalized name: glucose 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-g glucose challenge test
Trial: 2099963
Drug: Defibrotide administered
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide administered orally (400 mg b.i.d. for 15 days)
Trial: 2099963
Drug: Defibrotide administered
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide administered intramuscularly (200 mg b.i.d. for 15 days)
Trial: 317255
Drug: Clofibate (lipid-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (lipid-lowering substance) administered in a double-blind trial for an average of 5.3 years.
Trial: 28929830
Drug: Collaborative intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collaborative intervention process (six weekly sessions)
Trial: 17127227
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g t.i.d. of imipenem/cilastatin (group A)
Trial: 17127227
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g t.i.d. of meropenem (group B)
Trial: 14985312
Drug: PKC412 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC412 150 mg/d
Trial: 14985312
Drug: PKC412 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC412 100 mg/d
Trial: 14985312
Drug: PKC412 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC412 100 mg/d and 150 mg/d
Trial: 14985312
Drug: PKC412 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKC412 50 mg/d, 100 mg/d, 150 mg/d
Trial: 9924222
Drug: Bupivacaine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine up to 2 mg kg‐1, infiltrated around the inferior alveolar nerves bilaterally
Trial: 9924222
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg i.v. at the start of surgery
Trial: 25130262
Drug: 1.4 g
RxNorm normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g day(-1) omega-3 PUFAs plus cognitive behavioural case management
Trial: 15087034
Drug: HMVP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMVP regimen (hydroxycamptothecin 12 mg/m² d1-d5, mitomycin C 6 mg/m² d1, vindesine 2.5-3 mg/m² d1 and d8, cisplatin 50 mg/m² d2 and d3)
Trial: 9058157
Drug: Locoregional targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional targeted chemotherapy only via an arterial catheter (Group A)
Trial: 9058157
Drug: Combined locoregional
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined locoregional immuno-chemotherapy via two arterial catheters (Group B)
Trial: 7839878
Drug: Traditional anti-diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anti-diabetic medicines (hospital-based trial for about 4 weeks)
Trial: 7839878
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (ambulatory basis for up to 16 weeks)
Trial: 2944006
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (250,000 U) followed by i.v. administration of streptokinase (500,000 U) in group 2.
Trial: 2944006
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in group 1.
Trial: 3351336
Drug: Clobetasol Proprionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol Proprionate ointment
Trial: 28751575
Drug: Intranasal lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal lispro insulin (40 IU)
Trial: 24069451
Drug: Structured pro-active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pro-active care by practice nurses (3 monthly review appointments over 2 years)
Trial: 19446387
Drug: Epinephrine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (1 mg)
Trial: 16397814
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (750 ml total, 250 ml cranberry juice + 500 ml mineral water)
Trial: 16397814
Drug: Placebo (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (750 ml total, 750 ml placebo)
Trial: 16397814
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (750 ml total, 750 ml cranberry juice)
Trial: 16397814
Drug: Placebo (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (750 ml total, 250 ml placebo + 500 ml mineral water)
Trial: 11763381
Drug: Finasteride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1 mg)
Trial: 8489204
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of zidovudine five times daily
Trial: 8489204
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of zidovudine five times daily
Trial: 8489204
Drug: Placebo five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo five times daily
Trial: 8489204
Drug: Rerandomized to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rerandomized to zidovudine treatment after week 16
Trial: 12633191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fecal occult blood testing and sigmoidoscopy
Trial: 10997423
Drug: Positive oral
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive oral MR contrast media (Magnevist)
Trial: 10997423
Drug: Negative oral
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative oral MR contrast media (Abdoscan)
Trial: 8233262
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist leuprolide acetate depot for 3 months
Trial: 3545094
Drug: Educational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational programme by community child health nurses, visited monthly for six months.
Trial: 7989405
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg single oral dose)
Trial: 2686576
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride (mean dose 150 +/- 53 mg/d)
Trial: 2686576
Drug: Desipramine hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine hydrochloride (mean dose 153 +/- 55 mg/d)
Trial: 28390501
Drug: Internet-based extinction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based extinction therapy (IbET)
Trial: 27542131
Drug: Social learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social learning and cognitive behavioral therapy condition
Trial: 24602997
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (activation of a sham electrode) under continuous reinforcement (CRF)
Trial: 24602997
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (activation of a sham electrode) under partial reinforcement (PRF)
Trial: 20712749
Drug: Lamotrigine (up-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (up-titrated to 400 mg/day)
Trial: 20712749
Drug: Lithium (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (doses adjusted to obtain serum levels of 0.5-1.0 mmol/L)
Trial: 17344507
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (45 mg elemental Zn/d) for 12 months
Trial: 1427379
Drug: Miglitol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (100 mg)
Trial: 27832555
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 0.2 µg/ml effect-site concentration
Trial: 27832555
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at 0.4 µg/ml effect-site concentration
Trial: 23974276
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone therapy (Omnadren 250) for 9 weeks
Trial: 19365786
Drug: Clarithromycin treatment
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin treatment for 3 months
Trial: 16877720
Drug: Paclitaxel (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (weekly for 24 weeks after initial treatment for those with objective response or stable disease)
Trial: 11424516
Drug: YGD capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGD capsules (three capsules before each main meal for 10 days)
Trial: 11424516
Drug: YGD capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGD capsules (three capsules before each main meal for 45 days)
Trial: 11424516
Drug: YGD capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGD capsules (active treatment for 12 months)
Trial: 11424516
Drug: YGD capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YGD capsules
Trial: 7712308
Drug: UDCA (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (450 mg/day) for 6 months
Trial: 10813709
Drug: Intraarterial cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial cisplatin infusion
Trial: 2676224
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin infusion
Trial: 2676224
Drug: Intraarterial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial and intravenous cisplatin infusions
Trial: 28870
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium (CZP) with 60 ml of water
Trial: 28870
Drug: Clorazepate dipotassium
RxNorm normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate dipotassium (CZP) with 60 ml of magnesium aluminum hydroxide (Maalox)
Trial: 26305064
Drug: Rivastigmine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (single oral dose)
Trial: 26305064
Drug: Rivastigmine (1-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (1-month treatment)
Trial: 16690717
Drug: Oral-only breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-only breathing (nose clip)
Trial: 9459317
Drug: Third generation
RxNorm normalized name: Third generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third generation oral contraceptives (OCs)
Trial: 9459317
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral contraceptives (OCs)
Trial: 798592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Asa foetida and Nux vomica (0.01% alcoholic dilution)
Trial: 28760751
Drug: Multitarget therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitarget therapy (tacrolimus, 2‐3mg/d; mycophenolate mofetil, 0.50‐0.75 g/d; prednisone, 10mg/d)
Trial: 28760751
Drug: Azathioprine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2 mg/kg per day) plus prednisone (10 mg/d)
Trial: 31580800
Drug: Multitarget therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitarget therapy
Trial: 9424001
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg p.o.
Trial: 9424001
Drug: Metoclopramide 30
RxNorm normalized name: metoclopramide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 30 mg p.o.
Trial: 9424001
Drug: Metoclopramide 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 60 mg p.o. (after dose increase)
Trial: 3743627
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin (1.2 g)
Trial: 3743627
Drug: Aspirin tablets
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin tablets (1.2 g)
Trial: 10893655
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin
Trial: 1576068
Drug: Aspirin tablets
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin tablets
Trial: 26967681
Drug: Desipramine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 200 mg
Trial: 22138847
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing and direct periodontal intrapocket application of 15% metronidazole‐based gel in two sites (>5 mm in depth)
Trial: 21090335
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (Sishencong, Baihui, Shenting, etc.), once daily for 2 months.
Trial: 21090335
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/d), administered orally for 2 months.
Trial: 16178494
Drug: Ciprofloxacin/β-lactam combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin/β-lactam combination
Trial: 10577438
Drug: Niacin treatment
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin treatment (100 mg to 1000 mg daily)
Trial: 1752603
Drug: CC-hMG combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-hMG combination cycle
Trial: 1752603
Drug: CC-hMG cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-hMG cycle